Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets

NCT03581591 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1

Enrollment

OTHER

Sponsor class

Conditions

Hypophosphatemia
Hypophosphatemic Rickets
Pain, Chronic

Interventions

BIOLOGICAL: Burosumab

Sponsor

Redwood Dermatology Sciences

Collaborators

[object Object]